8th Annual Neuromuscular Disorders Seminar

Needs Statement

General neurologists need periodic and regular updates about many hot topics in neuromuscular disorders. Evidence-based literature grows by the day and indications and contraindications change. Also, new medications are emerging and approved regularly which exacerbates the need to learn about their place in the treatment paradigm and to navigate the high-price dilemma. There is also a need to broaden the scope of the general neurologists on the emerging literature of hereditary neuropathies and idiopathic inflammatory myopathies.  There is growing literature on increased utilization of genetic testing in the diagnosis of neuromuscular diseases which need to be addressed.  This seminar is designed to have national and world experts talk about emerging therapies and updates on different neuromuscular disorders such as chronic inflammatory demyelinating polyneuropathy, neuromuscular complications of cancer, amyotrophic lateral sclerosis, and myasthenia gravis.

Educational Objectives

At the conclusion of this activity, the participant should be able to:

• Apply new genetic tests to diagnose hereditary neuromuscular disorders.
• Identify appropriate medication for the treatment of refractory myasthenia gravis.
• Identify the genetic implications of hereditary neuropathies.
• Identify the diagnostic waveforms associated with various disorders.

Target Audience

Accreditation/Credit Designation

AMA PRA Category 1 Credits™

Baylor College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Baylor College of Medicine designates this live activity for a maximum of 7.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AMERICAN BOARD OF PSYCHIATRY AND NEUROLOGY

The activity awards up to 7 Category 1 CME as Self-Assessment credits.

Disclosure Policy

Baylor College of Medicine (BCM) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians. BCM is committed to sponsoring CE activities that are scientifically based, accurate, current, and objectively presented.

In accordance with the ACCME Standards for Commercial Support, BCM has implemented a mechanism requiring everyone in a position to control the content of an educational activity (i.e., directors, planning committee members, faculty) to disclose any relevant financial relationships with commercial interests (drug/device companies) and manage/resolve any conflicts of interest prior to the activity. Individuals must disclose to participants the existence or non-existence of financial relationships at the time of the activity or within 24 months prior.

In addition, BCM has requested activity faculty/presenters to disclose to participants any unlabeled use or investigational use of pharmaceutical/device products; to use scientific or generic names (not trade names) in referring to products; and, if necessary to use a trade name, to use the names of similar products or those within a class. Faculty/presenters have also been requested to adhere to the ACCME's validation of clinical content statements.

BCM does not view the existence of financial relationships with commercial interests as implying bias or decreasing the value of a presentation. It is up to participants to determine whether the relationships influence the activity faculty with regard to exposition or conclusions. If at any time during this activity you feel that there has been commercial/promotional bias, notify the Activity Director or Activity Coordinator. Please answer the questions about balance and objectivity in the activity evaluation candidly.

All of the relevant financial relationships listed for these individuals have been mitigated.